Exploring Blood Glutamate as a Diagnostic Biomarker for Major Depressive Episodes in a Context of Major Depressive Disorder
Further research is warranted to investigate brain glutamate levels and whether glutamate levels of MDE/MDD patients could predict response to conventional antidepressant drugs and anti-glutamatergic drugs such as ketamine.
Authors
- Bruno Fève (ORCID: https://orcid.org/0000-0001-6577-9009)
- Romain Colle (ORCID: https://orcid.org/0000-0002-2549-4495)
- Hugo Bottemanne (ORCID: https://orcid.org/0000-0003-2958-0849)
- Laurent Becquemont (ORCID: https://orcid.org/0000-0003-3477-8956)
- Séverine Trabado (ORCID: https://orcid.org/0000-0002-1925-1999)
- Tala El Ghoul
- Khalil El Asmar (ORCID: https://orcid.org/0000-0002-6030-8088)
- Emmanuelle Corruble (ORCID: https://orcid.org/0000-0002-9441-6079)
- Céline Verstuyft (ORCID: https://orcid.org/0000-0002-8534-224X)
- Séverine Martin
- Rida Assaf
Institutions
- Inserm (FR)
- Université Paris-Saclay (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre de recherche en Epidémiologie et Santé des Populations (FR)
- Bicêtre Hospital (FR)
- American University of Beirut (LB)
Publication Details
- Journal
- Neuropsychobiology
- Published
- 2025-09-05
- DOI
- https://doi.org/10.1159/000548339
- Primary Topic
- Diet and metabolism studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00